Embolotherapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product {Embolic Agents (Microspheres, Liquid Embolic Agents, Coil), Microcatheters}, By Indication (Oncology, Vascular, Aneurysm, Urology, Nephrology), By Procedure (TACE, TARE), By End User (Hospital, Clinics, Ambulatory Surgery Centers), By Region and Competition
The Global Embolotherapy Market was valued at USD 3.67 Billion in 2022 and is expected to experience substantial growth in the forecast period, with a Compound Annual Growth Rate (CAGR) of 8.35% and expected to reach USD 5.99 Billion through 2028. Embolotherapy, a minimally invasive treatment that selectively restricts blood flow to specific areas, is gaining recognition and popularity globally. This endovascular procedure is utilized to occlude abnormal blood vessels, effectively controlling or stopping bleeding. In urgent cases of severe hemorrhage, Embolotherapy is emerging as a viable alternative to invasive surgery, particularly for cases like severe bleeding. Interventional radiologists perform this procedure in various clinical settings. The applications of Embolotherapy have expanded significantly, especially in cutting-edge procedures like prostatic artery embolization (PAE) for benign prostatic hyperplasia and gastric artery embolization (GAE) for weight loss. These procedures have proven to be effective in treating their respective conditions. For instance, PAE is performed globally to address lower urinary tract symptoms (LUTS) caused by BPH, with over 800 procedures annually. Embolotherapy is also used in managing chronic pain conditions, treating uterine fibroids, and addressing specific types of cancer, such as liver cancer.
Key Market Drivers
Growing Target Patient Population
The prevalence of cardiovascular disease (CVD) and the increasing importance of successful treatments have led to a focus on research into effective interventions. Peripheral vascular diseases affected over 200 million individuals globally in 2017. With age, the prevalence of these diseases rises, particularly in those aged 80 and above. The demand for Embolotherapy devices is driven by its success rate, low postoperative complications, and the rising incidence of conditions like liver cancer and hepatocellular cancer. Liver cancer is among the most common cancers in men and women, with over 840,000 new cases diagnosed worldwide in 2018. Kidney cancer incidence rates have also increased, particularly in the United Kingdom. These trends contribute to the demand for Embolotherapy.
Rising Patient Preference for Minimally Invasive Procedures
The increasing preference for minimally invasive surgeries is driving the demand for procedures like Embolotherapy. Patients opt for these procedures due to reduced postoperative pain, fewer complications, shorter hospital stays, and faster recovery times. Techniques like Trans Arterial Chemo Embolization (TACE) are evolving as minimally invasive alternatives, revolutionizing treatments like hepatocellular carcinoma. Prostatic Artery Embolization (PAE) serves as a minimally invasive therapy for benign prostatic hyperplasia (BPH) and its associated symptoms. The growing preference for these procedures is expanding the embolotherapy market.
Funding & Investments by Government and Private Organizations
Adequate funding and investments drive research, development, and refinement of medical procedures like Embolotherapy. Positive trial results instill confidence in medical professionals and patients, driving demand for adoption. Training programs and medical education disseminate knowledge among professionals, leading to increased demand. Government funding and support influence insurance coverage and reimbursement policies, making Embolotherapy more accessible.
Technological Advancements in Embolotherapy Devices
Technological advancements in embolotherapy devices have improved precision, effectiveness, and minimally invasive qualities. Enhanced microcatheters, advanced imaging techniques, navigation systems, robotics, and visualization tools have transformed the field. These advancements improve procedural outcomes, patient safety, and recovery times. As technology evolves, the embolotherapy field will likely see further innovations enhancing these procedures.
Key Market Challenges
Stringent Regulations
Artificial embolization devices are classified as medical devices and are subject to stringent regulations. Regulatory classifications impact device approval and authorization, influencing the market landscape.
Lack Of Skilled Medical Professionals
A shortage of skilled professionals can limit access to embolotherapy treatments, affecting patient outcomes and increasing risks.
Key Market Trends
Increasing Acquisitions and Collaborations
Collaborations enhance research, development, accessibility, and awareness of embolotherapy. Collaborative efforts accelerate innovation and solutions tailored to diverse patient needs.
Advancement in Oncology
The need for innovative cancer treatments drives demand for personalized solutions like embolotherapy. Precision and minimal invasiveness make embolotherapy attractive in personalized oncology care.
Segmental Insights
Product Insights
The embolic agent segment dominates the market due to the increasing prevalence of conditions requiring microspheres, especially in hepatocellular carcinoma treatment.
End User Insights
Hospitals are the primary users of embolotherapy devices. The increasing utilization of minimally invasive procedures, growing healthcare provider purchasing power, and availability of reimbursements contribute to this segment's growth.
Regional Insights
North America
North America leads the market due to the prevalence of conditions requiring embolization, a well-established healthcare system, and ongoing advancements in embolic agents.
Asia-Pacific
The Asia-Pacific region is expected to experience the fastest growth due to increasing patient populations, government healthcare investments, and rising cancer incidence.
Key Market Players
In this report, the Global Embolotherapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Embolotherapy Market.
Available Customizations:
Global Embolotherapy market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Key Market Drivers
Growing Target Patient Population
The prevalence of cardiovascular disease (CVD) and the increasing importance of successful treatments have led to a focus on research into effective interventions. Peripheral vascular diseases affected over 200 million individuals globally in 2017. With age, the prevalence of these diseases rises, particularly in those aged 80 and above. The demand for Embolotherapy devices is driven by its success rate, low postoperative complications, and the rising incidence of conditions like liver cancer and hepatocellular cancer. Liver cancer is among the most common cancers in men and women, with over 840,000 new cases diagnosed worldwide in 2018. Kidney cancer incidence rates have also increased, particularly in the United Kingdom. These trends contribute to the demand for Embolotherapy.
Rising Patient Preference for Minimally Invasive Procedures
The increasing preference for minimally invasive surgeries is driving the demand for procedures like Embolotherapy. Patients opt for these procedures due to reduced postoperative pain, fewer complications, shorter hospital stays, and faster recovery times. Techniques like Trans Arterial Chemo Embolization (TACE) are evolving as minimally invasive alternatives, revolutionizing treatments like hepatocellular carcinoma. Prostatic Artery Embolization (PAE) serves as a minimally invasive therapy for benign prostatic hyperplasia (BPH) and its associated symptoms. The growing preference for these procedures is expanding the embolotherapy market.
Funding & Investments by Government and Private Organizations
Adequate funding and investments drive research, development, and refinement of medical procedures like Embolotherapy. Positive trial results instill confidence in medical professionals and patients, driving demand for adoption. Training programs and medical education disseminate knowledge among professionals, leading to increased demand. Government funding and support influence insurance coverage and reimbursement policies, making Embolotherapy more accessible.
Technological Advancements in Embolotherapy Devices
Technological advancements in embolotherapy devices have improved precision, effectiveness, and minimally invasive qualities. Enhanced microcatheters, advanced imaging techniques, navigation systems, robotics, and visualization tools have transformed the field. These advancements improve procedural outcomes, patient safety, and recovery times. As technology evolves, the embolotherapy field will likely see further innovations enhancing these procedures.
Key Market Challenges
Stringent Regulations
Artificial embolization devices are classified as medical devices and are subject to stringent regulations. Regulatory classifications impact device approval and authorization, influencing the market landscape.
Lack Of Skilled Medical Professionals
A shortage of skilled professionals can limit access to embolotherapy treatments, affecting patient outcomes and increasing risks.
Key Market Trends
Increasing Acquisitions and Collaborations
Collaborations enhance research, development, accessibility, and awareness of embolotherapy. Collaborative efforts accelerate innovation and solutions tailored to diverse patient needs.
Advancement in Oncology
The need for innovative cancer treatments drives demand for personalized solutions like embolotherapy. Precision and minimal invasiveness make embolotherapy attractive in personalized oncology care.
Segmental Insights
Product Insights
The embolic agent segment dominates the market due to the increasing prevalence of conditions requiring microspheres, especially in hepatocellular carcinoma treatment.
End User Insights
Hospitals are the primary users of embolotherapy devices. The increasing utilization of minimally invasive procedures, growing healthcare provider purchasing power, and availability of reimbursements contribute to this segment's growth.
Regional Insights
North America
North America leads the market due to the prevalence of conditions requiring embolization, a well-established healthcare system, and ongoing advancements in embolic agents.
Asia-Pacific
The Asia-Pacific region is expected to experience the fastest growth due to increasing patient populations, government healthcare investments, and rising cancer incidence.
Key Market Players
- Medtronic, PLC
- Microport Scientific
- Boston Scientific Corporation
- Stryker
- Terumo Corporation
- Penumbra, Inc.
- Sirtex (CDH)
- Johnson & Johnson
- Abbott Laboratories
- Balt Group
In this report, the Global Embolotherapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Embolotherapy Market, By Product:
- Embolic Agents
- Microspheres
- Liquid Embolic Agents
- Coil
- Microcatheters
- Embolotherapy Market, By Indication:
- Oncology
- Vascular
- Aneurysm
- Urology
- Nephrology
- Embolotherapy Market, By Procedure:
- TACE
- TARE
- Embolotherapy Market, By End User:
- Hospital
- Clinics
- Ambulatory Surgery Centres
- Embolotherapy Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
- Turkey
- Egypt
Company Profiles: Detailed analysis of the major companies present in the Global Embolotherapy Market.
Available Customizations:
Global Embolotherapy market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL EMBOLOTHERAPY MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product (Embolic Agents, Microcatheters)
5.2.1.1. By Embolic Agents (Microspheres, Liquid Embolic Agents, Coil)
5.2.2. By Indication (Oncology, Vascular, Aneurysm, Urology, Nephrology)
5.2.3. By Procedure (TACE, TARE)
5.2.4. By End User (Hospital, Clinics, Ambulatory Surgery Centres)
5.2.5. By Region
5.2.6. By Company (2022)
5.3. Market Map
6. NORTH AMERICA EMBOLOTHERAPY MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product
6.2.1.1. By Embolic Agents
6.2.2. By Indication
6.2.3. By Procedure
6.2.4. By End User
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Embolotherapy Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product
6.3.1.2.1.1. By Embolic Agents
6.3.1.2.2. By Indication
6.3.1.2.3. By Procedure
6.3.1.2.4. By End User
6.3.2. Canada Embolotherapy Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product
6.3.2.2.1.1. By Embolic Agents
6.3.2.2.2. By Indication
6.3.2.2.3. By Procedure
6.3.2.2.4. By End User
6.3.3. Mexico Embolotherapy Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product
6.3.3.2.1.1. By Embolic Agents
6.3.3.2.2. By Indication
6.3.3.2.3. By Procedure
6.3.3.2.4. By End User
7. EUROPE EMBOLOTHERAPY MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product
7.2.1.1. By Embolic Agents
7.2.2. By Indication
7.2.3. By Procedure
7.2.4. By End User
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Embolotherapy Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product
7.3.1.2.1.1. By Embolic Agents
7.3.1.2.2. By Indication
7.3.1.2.3. By Procedure
7.3.1.2.4. By End User
7.3.2. United Kingdom Embolotherapy Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product
7.3.2.2.1.1. By Embolic Agents
7.3.2.2.2. By Indication
7.3.2.2.3. By Procedure
7.3.2.2.4. By End User
7.3.3. Italy Embolotherapy Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecasty
7.3.3.2.1. By Product
7.3.3.2.1.1. By Embolic Agents
7.3.3.2.2. By Indication
7.3.3.2.3. By Procedure
7.3.3.2.4. By End User
7.3.4. France Embolotherapy Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product
7.3.4.2.1.1. By Embolic Agents
7.3.4.2.2. By Indication
7.3.4.2.3. By Procedure
7.3.4.2.4. By End User
7.3.5. Spain Embolotherapy Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product
7.3.5.2.1.1. By Embolic Agents
7.3.5.2.2. By Indication
7.3.5.2.3. By Procedure
7.3.5.2.4. By End User
8. ASIA-PACIFIC EMBOLOTHERAPY MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product
8.2.1.1. By Embolic Agents
8.2.2. By Indication
8.2.3. By Procedure
8.2.4. By End User
8.2.5. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Embolotherapy Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product
8.3.1.2.1.1. By Embolic Agents
8.3.1.2.2. By Indication
8.3.1.2.3. By Procedure
8.3.1.2.4. By End User
8.3.2. India Embolotherapy Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product
8.3.2.2.1.1. By Embolic Agents
8.3.2.2.2. By Indication
8.3.2.2.3. By Procedure
8.3.2.2.4. By End User
8.3.3. Japan Embolotherapy Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product
8.3.3.2.1.1. By Embolic Agents
8.3.3.2.2. By Indication
8.3.3.2.3. By Procedure
8.3.3.2.4. By End User
8.3.4. South Korea Embolotherapy Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product
8.3.4.2.1.1. By Embolic Agents
8.3.4.2.2. By Indication
8.3.4.2.3. By Procedure
8.3.4.2.4. By End User
8.3.5. Australia Embolotherapy Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product
8.3.5.2.1.1. By Embolic Agents
8.3.5.2.2. By Indication
8.3.5.2.3. By Procedure
8.3.5.2.4. By End User
9. SOUTH AMERICA EMBOLOTHERAPY MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product
9.2.1.1. By Embolic Agents
9.2.2. By Indication
9.2.3. By Procedure
9.2.4. By End User
9.2.5. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Embolotherapy Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product
9.3.1.2.1.1. By Embolic Agents
9.3.1.2.2. By Indication
9.3.1.2.3. By Procedure
9.3.1.2.4. By End User
9.3.2. Argentina Embolotherapy Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product
9.3.2.2.1.1. By Embolic Agents
9.3.2.2.2. By Indication
9.3.2.2.3. By Procedure
9.3.2.2.4. By End User
9.3.3. Colombia Embolotherapy Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product
9.3.3.2.1.1. By Embolic Agents
9.3.3.2.2. By Indication
9.3.3.2.3. By Procedure
9.3.3.2.4. By End User
10. MIDDLE EAST AND AFRICA EMBOLOTHERAPY MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product
10.2.1.1. By Embolic Agents
10.2.2. By Indication
10.2.3. By Procedure
10.2.4. By End User
10.2.5. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Embolotherapy Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product
10.3.1.2.1.1. By Embolic Agents
10.3.1.2.2. By Indication
10.3.1.2.3. By Procedure
10.3.1.2.4. By End User
10.3.2. Saudi Arabia Embolotherapy Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product
10.3.2.2.1.1. By Embolic Agents
10.3.2.2.2. By Indication
10.3.2.2.3. By Procedure
10.3.2.2.4. By End User
10.3.3. UAE Embolotherapy Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product
10.3.3.2.1.1. By Embolic Agents
10.3.3.2.2. By Indication
10.3.3.2.3. By Procedure
10.3.3.2.4. By End User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches
13. GLOBAL ORAL CLINICAL NUTRITION MARKET: SWOT ANALYSIS
14. PORTER’S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Business Overview
15.2. Service Offerings
15.3. Recent Developments
15.4. Key Personnel
15.5. SWOT Analysis
15.5.1. Medtronic, PLC
15.5.2. Microport Scientific
15.5.3. Boston Scientific Corporation
15.5.4. Stryker
15.5.5. Terumo Corporation
15.5.6. Penumbra, Inc.
15.5.7. Sirtex (CDH)
15.5.8. Johnson & Johnson
15.5.9. Abbott Laboratories
15.5.10. Balt Group
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validations
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL EMBOLOTHERAPY MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product (Embolic Agents, Microcatheters)
5.2.1.1. By Embolic Agents (Microspheres, Liquid Embolic Agents, Coil)
5.2.2. By Indication (Oncology, Vascular, Aneurysm, Urology, Nephrology)
5.2.3. By Procedure (TACE, TARE)
5.2.4. By End User (Hospital, Clinics, Ambulatory Surgery Centres)
5.2.5. By Region
5.2.6. By Company (2022)
5.3. Market Map
6. NORTH AMERICA EMBOLOTHERAPY MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product
6.2.1.1. By Embolic Agents
6.2.2. By Indication
6.2.3. By Procedure
6.2.4. By End User
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Embolotherapy Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product
6.3.1.2.1.1. By Embolic Agents
6.3.1.2.2. By Indication
6.3.1.2.3. By Procedure
6.3.1.2.4. By End User
6.3.2. Canada Embolotherapy Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product
6.3.2.2.1.1. By Embolic Agents
6.3.2.2.2. By Indication
6.3.2.2.3. By Procedure
6.3.2.2.4. By End User
6.3.3. Mexico Embolotherapy Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product
6.3.3.2.1.1. By Embolic Agents
6.3.3.2.2. By Indication
6.3.3.2.3. By Procedure
6.3.3.2.4. By End User
7. EUROPE EMBOLOTHERAPY MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product
7.2.1.1. By Embolic Agents
7.2.2. By Indication
7.2.3. By Procedure
7.2.4. By End User
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Embolotherapy Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product
7.3.1.2.1.1. By Embolic Agents
7.3.1.2.2. By Indication
7.3.1.2.3. By Procedure
7.3.1.2.4. By End User
7.3.2. United Kingdom Embolotherapy Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product
7.3.2.2.1.1. By Embolic Agents
7.3.2.2.2. By Indication
7.3.2.2.3. By Procedure
7.3.2.2.4. By End User
7.3.3. Italy Embolotherapy Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecasty
7.3.3.2.1. By Product
7.3.3.2.1.1. By Embolic Agents
7.3.3.2.2. By Indication
7.3.3.2.3. By Procedure
7.3.3.2.4. By End User
7.3.4. France Embolotherapy Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product
7.3.4.2.1.1. By Embolic Agents
7.3.4.2.2. By Indication
7.3.4.2.3. By Procedure
7.3.4.2.4. By End User
7.3.5. Spain Embolotherapy Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product
7.3.5.2.1.1. By Embolic Agents
7.3.5.2.2. By Indication
7.3.5.2.3. By Procedure
7.3.5.2.4. By End User
8. ASIA-PACIFIC EMBOLOTHERAPY MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product
8.2.1.1. By Embolic Agents
8.2.2. By Indication
8.2.3. By Procedure
8.2.4. By End User
8.2.5. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Embolotherapy Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product
8.3.1.2.1.1. By Embolic Agents
8.3.1.2.2. By Indication
8.3.1.2.3. By Procedure
8.3.1.2.4. By End User
8.3.2. India Embolotherapy Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product
8.3.2.2.1.1. By Embolic Agents
8.3.2.2.2. By Indication
8.3.2.2.3. By Procedure
8.3.2.2.4. By End User
8.3.3. Japan Embolotherapy Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product
8.3.3.2.1.1. By Embolic Agents
8.3.3.2.2. By Indication
8.3.3.2.3. By Procedure
8.3.3.2.4. By End User
8.3.4. South Korea Embolotherapy Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product
8.3.4.2.1.1. By Embolic Agents
8.3.4.2.2. By Indication
8.3.4.2.3. By Procedure
8.3.4.2.4. By End User
8.3.5. Australia Embolotherapy Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product
8.3.5.2.1.1. By Embolic Agents
8.3.5.2.2. By Indication
8.3.5.2.3. By Procedure
8.3.5.2.4. By End User
9. SOUTH AMERICA EMBOLOTHERAPY MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product
9.2.1.1. By Embolic Agents
9.2.2. By Indication
9.2.3. By Procedure
9.2.4. By End User
9.2.5. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Embolotherapy Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product
9.3.1.2.1.1. By Embolic Agents
9.3.1.2.2. By Indication
9.3.1.2.3. By Procedure
9.3.1.2.4. By End User
9.3.2. Argentina Embolotherapy Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product
9.3.2.2.1.1. By Embolic Agents
9.3.2.2.2. By Indication
9.3.2.2.3. By Procedure
9.3.2.2.4. By End User
9.3.3. Colombia Embolotherapy Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product
9.3.3.2.1.1. By Embolic Agents
9.3.3.2.2. By Indication
9.3.3.2.3. By Procedure
9.3.3.2.4. By End User
10. MIDDLE EAST AND AFRICA EMBOLOTHERAPY MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product
10.2.1.1. By Embolic Agents
10.2.2. By Indication
10.2.3. By Procedure
10.2.4. By End User
10.2.5. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Embolotherapy Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product
10.3.1.2.1.1. By Embolic Agents
10.3.1.2.2. By Indication
10.3.1.2.3. By Procedure
10.3.1.2.4. By End User
10.3.2. Saudi Arabia Embolotherapy Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product
10.3.2.2.1.1. By Embolic Agents
10.3.2.2.2. By Indication
10.3.2.2.3. By Procedure
10.3.2.2.4. By End User
10.3.3. UAE Embolotherapy Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product
10.3.3.2.1.1. By Embolic Agents
10.3.3.2.2. By Indication
10.3.3.2.3. By Procedure
10.3.3.2.4. By End User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches
13. GLOBAL ORAL CLINICAL NUTRITION MARKET: SWOT ANALYSIS
14. PORTER’S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Business Overview
15.2. Service Offerings
15.3. Recent Developments
15.4. Key Personnel
15.5. SWOT Analysis
15.5.1. Medtronic, PLC
15.5.2. Microport Scientific
15.5.3. Boston Scientific Corporation
15.5.4. Stryker
15.5.5. Terumo Corporation
15.5.6. Penumbra, Inc.
15.5.7. Sirtex (CDH)
15.5.8. Johnson & Johnson
15.5.9. Abbott Laboratories
15.5.10. Balt Group
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
